1. Home
  2. ABUS vs CRGX Comparison

ABUS vs CRGX Comparison

Compare ABUS & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABUS
  • CRGX
  • Stock Information
  • Founded
  • ABUS N/A
  • CRGX 2021
  • Country
  • ABUS United States
  • CRGX United States
  • Employees
  • ABUS N/A
  • CRGX N/A
  • Industry
  • ABUS Biotechnology: Pharmaceutical Preparations
  • CRGX
  • Sector
  • ABUS Health Care
  • CRGX
  • Exchange
  • ABUS Nasdaq
  • CRGX Nasdaq
  • Market Cap
  • ABUS 629.1M
  • CRGX 621.4M
  • IPO Year
  • ABUS N/A
  • CRGX 2023
  • Fundamental
  • Price
  • ABUS $3.21
  • CRGX $12.86
  • Analyst Decision
  • ABUS Strong Buy
  • CRGX Strong Buy
  • Analyst Count
  • ABUS 4
  • CRGX 6
  • Target Price
  • ABUS $5.50
  • CRGX $31.80
  • AVG Volume (30 Days)
  • ABUS 876.5K
  • CRGX 279.0K
  • Earning Date
  • ABUS 02-27-2025
  • CRGX 11-12-2024
  • Dividend Yield
  • ABUS N/A
  • CRGX N/A
  • EPS Growth
  • ABUS N/A
  • CRGX N/A
  • EPS
  • ABUS N/A
  • CRGX N/A
  • Revenue
  • ABUS $6,742,000.00
  • CRGX N/A
  • Revenue This Year
  • ABUS N/A
  • CRGX N/A
  • Revenue Next Year
  • ABUS N/A
  • CRGX N/A
  • P/E Ratio
  • ABUS N/A
  • CRGX N/A
  • Revenue Growth
  • ABUS N/A
  • CRGX N/A
  • 52 Week Low
  • ABUS $2.27
  • CRGX $10.91
  • 52 Week High
  • ABUS $4.72
  • CRGX $33.92
  • Technical
  • Relative Strength Index (RSI)
  • ABUS 43.07
  • CRGX 42.73
  • Support Level
  • ABUS $3.16
  • CRGX $10.91
  • Resistance Level
  • ABUS $3.38
  • CRGX $15.75
  • Average True Range (ATR)
  • ABUS 0.14
  • CRGX 1.16
  • MACD
  • ABUS 0.00
  • CRGX -0.03
  • Stochastic Oscillator
  • ABUS 19.51
  • CRGX 39.63

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Share on Social Networks: